Regulatory requirements for PET drug production

Sally W. Schwarz, David Dick, Henry F. VanBrocklin, John M. Hoffman

Research output: Contribution to journalReview articlepeer-review

19 Scopus citations


The Food and Drug Administration (FDA) issued the final rule for title 21 of Code of Federal Regulations part 212 regarding the regulations on current good manufacturing practice for PET drugs. The regulations are intended to ensure that PET drugs meet the safety and quality assurance requirements of the Federal Food, Drug, and Cosmetic Act. The new regulation became effective December 12, 2011, but the FDA used regulatory discretion to allow new drug applications and abbreviated new drug applications to be filed until June 12, 2012, without interruption of the existing PET drug production for human use. The production of PET drugs for both clinical use and clinical research use are outlined in this continuing education module, including an overview of specific requirements for compliance. Additionally, FDA preapproval inspections and post-approval reporting requirements are reviewed.

Original languageEnglish
Pages (from-to)1132-1137
Number of pages6
JournalJournal of Nuclear Medicine
Issue number7
StatePublished - Jul 1 2014


  • Annual reporting
  • FDA inspections
  • FDA part 212
  • USP chapter 〈823〉


Dive into the research topics of 'Regulatory requirements for PET drug production'. Together they form a unique fingerprint.

Cite this